Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

References

• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177 - 82; http://dx.doi.org/10.1126/science.3798106; PMID: 3798106
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783 - 92; http://dx.doi.org/10.1056/NEJM200103153441101; PMID: 11248153
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265 - 74; http://dx.doi.org/10.1200/JCO.2005.04.173; PMID: 15911866
   PubMed Web of Science ®Google Scholar
• Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007; 25:3246 - 50; http://dx.doi.org/10.1200/JCO.2006.09.6826; PMID: 17577021
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30:1426 - 47; http://dx.doi.org/10.1016/j.clinthera.2008.08.008; PMID: 18803986
   PubMed Web of Science ®Google Scholar
• Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31:2332 - 48; http://dx.doi.org/10.1016/j.clinthera.2009.11.029; PMID: 20110044
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6:667 - 74; http://dx.doi.org/10.1158/1535-7163.MCT-06-0423; PMID: 17308062
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733 - 43; http://dx.doi.org/10.1056/NEJMoa064320; PMID: 17192538
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533 - 43; http://dx.doi.org/10.1007/s10549-007-9885-0; PMID: 18188694
   PubMed Web of Science ®Google Scholar
• Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010; 21:474 - 80; http://dx.doi.org/10.1093/annonc/mdp373; PMID: 19815649
   PubMed Web of Science ®Google Scholar
• Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 2011; 30:327 - 35; http://dx.doi.org/10.5732/cjc.010.10507; PMID: 21527065
   PubMedGoogle Scholar
• Kostyal D, Welt RS, Danko J, Shay T, Lanning C, Horton K, Welt S. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol 2012; 29:1486 - 94; http://dx.doi.org/10.1007/s12032-011-0025-7; PMID: 21769502
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15:924 - 34; http://dx.doi.org/10.1634/theoncologist.2009-0181; PMID: 20736298
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174 - 83; http://dx.doi.org/10.1016/S1470-2045(09)70262-1; PMID: 20152769
   PubMed Web of Science ®Google Scholar
• Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H, Sabo E. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002; 41:519 - 25; http://dx.doi.org/10.1046/j.1365-2559.2002.01444.x; PMID: 12460204
   PubMed Web of Science ®Google Scholar
• Salminen E, Palmu S, Vahlberg T, Roberts PJ, Söderström KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 2005; 11:3245 - 9; PMID: 15929175
   PubMed Web of Science ®Google Scholar
• Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1:747 - 54; http://dx.doi.org/10.3892/etm.2010.133; PMID: 22993598
   PubMed Web of Science ®Google Scholar
• Bianchini G, Gianni L. Surrogate markers for targeted therapy-based treatment activity and efficacy. J Natl Cancer Inst Monogr 2011; 2011:91 - 4; http://dx.doi.org/10.1093/jncimonographs/lgr024; PMID: 22043050
   PubMedGoogle Scholar
• Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, et al. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011; 2011:120 - 3; http://dx.doi.org/10.1093/jncimonographs/lgr034; PMID: 22043057
   PubMedGoogle Scholar
• Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117 - 27; http://dx.doi.org/10.1016/j.ccr.2004.06.022; PMID: 15324695
   PubMed Web of Science ®Google Scholar
• Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1:747 - 54; http://dx.doi.org/10.3892/etm.2010.133; PMID: 22993598
   PubMed Web of Science ®Google Scholar